Advertisement

Investigational New Drugs

, Volume 11, Issue 2–3, pp 235–237 | Cite as

Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma

A Canadian National Cancer Institute Clinical Trial Group study
  • J. A. Maroun
  • J. Skillings
  • R. MacCormick
  • M. Potvin
  • G. Wielgosz
  • J. R. Davidson
  • E. Eisenhauer
Brief Report Phase II Studies

Key words

colorectal cancer phase II study DuP 937 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Leopold WR, Nelson JM, Plowman J,et al.: Anthapyrazoles, a new class of intercalating agents with high level, broad spectrum activity against murine tumors. Cancer Res 45:5532–5539, 1985Google Scholar
  2. 2.
    Showalter HDH, Johnson JL, Hofteizer JM,et al.: Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias. J Med Chem 30(1): 121–131, 1987Google Scholar
  3. 3.
    Erlichman C, Moore M, Kerr I, Wong B, Eisenhauer E, Zee B, Whitfield L: A Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole CI-937 (DuP 937). Cancer Research 51:6317–6322, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • J. A. Maroun
    • 1
  • J. Skillings
    • 2
  • R. MacCormick
    • 3
  • M. Potvin
    • 4
  • G. Wielgosz
    • 5
  • J. R. Davidson
    • 6
  • E. Eisenhauer
    • 6
  1. 1.Ottawa Regional Cancer CentreOttawa
  2. 2.London Regional Cancer CentreLondon
  3. 3.Nova Scotia Cancer Treatment and Research FoundationHalifax
  4. 4.Laval HospitalQuebec
  5. 5.DuPont PharmaMississauga
  6. 6.NCIC CTGKingstonCanada

Personalised recommendations